Want to see SE:ARCOMA full AI Analyst Report?
Top Page
Arcoma AB
(ARCOMA)
Select Model
Select Model
Rating:61Neutral
Price Target:
kr7.50
▲(4.17% Upside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by a strong, low-debt balance sheet and restored profitability, but held back by uneven revenue/margin trends and volatile cash flow. Technical indicators are broadly neutral and do not add strong support, while the relatively high P/E (~32) without a stated dividend yield weighs on the valuation component.
Positive Factors
Low Leverage
Near-zero debt across TTM and 2024–2025, alongside steadily rising equity, gives Arcoma financial flexibility. This reduces leverage pressure during uneven trading and preserves capacity to absorb volatility or invest without relying heavily on external financing.
Negative Factors
Uneven Revenue Trend
Revenue performance is uneven: 2025 revenue fell about 16.6% after strong 2023 growth, despite 17.2% TTM growth. This inconsistency makes forward planning less reliable and indicates that recent recovery has not yet established a steady multi-period growth trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Near-zero debt across TTM and 2024–2025, alongside steadily rising equity, gives Arcoma financial flexibility. This reduces leverage pressure during uneven trading and preserves capacity to absorb volatility or invest without relying heavily on external financing.
Read all positive factors
Arcoma AB (ARCOMA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr105.31M
Dividend YieldN/A
Average Volume (3M)5.20K
Price to Earnings (P/E)25.4
Beta (1Y)0.07
Revenue Growth-5.68%
EPS Growth-25.31%
CountrySE
Employees33
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.29
Shares Outstanding14,308,510
10 Day Avg. Volume6,176
30 Day Avg. Volume5,199
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.41
Price to Sales (P/S)0.80
P/FCF Ratio8.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.55
Revenue Forecast (FY)kr135.00M
Arcoma AB Business Overview & Revenue Model
Company Description
Arcoma AB is a global provider that designs, manufactures, and supplies cutting-edge radiology solutions. Their product line features advanced digital x-ray and radiography systems. These versatile systems are suitable for a wide array of radiogra...
How the Company Makes Money
Arcoma makes money primarily by selling diagnostic imaging equipment—most notably digital radiography (DR) X-ray systems—to healthcare providers and other medical imaging customers. Revenue is generated through (1) product sales of complete X-ray ...
Arcoma AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 127.27M | 130.80M | 156.81M | 163.01M | 125.05M | 117.13M |
| Gross Profit | 4.35M | 6.86M | 62.61M | 57.91M | 50.45M | 41.65M |
| EBITDA | 12.24M | 16.02M | 21.96M | 6.11M | 4.68M | -6.66M |
| Net Income | 4.11M | 5.03M | 11.18M | 2.56M | 1.90M | -7.47M |
Balance Sheet | ||||||
| Total Assets | 99.51M | 96.65M | 80.46M | 81.96M | 100.33M | 79.27M |
| Cash, Cash Equivalents and Short-Term Investments | 30.91M | 35.32M | 13.38M | 5.00M | 9.66M | 4.83M |
| Total Debt | 0.00 | 90.00K | 59.00K | 3.87M | 25.09M | 16.61M |
| Total Liabilities | 23.66M | 21.92M | 21.13M | 33.30M | 54.46M | 35.23M |
| Stockholders Equity | 75.85M | 74.73M | 59.33M | 48.66M | 45.88M | 44.04M |
Cash Flow | ||||||
| Free Cash Flow | 9.69M | 13.10M | 12.06M | 16.61M | -4.35M | -6.12M |
| Operating Cash Flow | 11.43M | 18.72M | 18.84M | 19.16M | -179.00K | -1.93M |
| Investing Cash Flow | -4.80M | -5.62M | -6.78M | -2.55M | -4.17M | -4.19M |
| Financing Cash Flow | 10.36M | 10.36M | -3.87M | -21.22M | 9.65M | 2.40M |
Arcoma AB Technical Analysis
Negative
7.20
Price Trends
8.08
Negative
8.40
Negative
8.08
Negative
Market Momentum
-0.26
Positive
39.42
Neutral
48.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ARCOMA, the sentiment is Negative. The current price of 7.2 is below the 20-day moving average (MA) of 7.74, below the 50-day MA of 8.08, and below the 200-day MA of 8.08, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 48.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ARCOMA.
Arcoma AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr4.20B | 32.01 | 14.59% | 1.59% | -1.64% | -14.61% | |
61 Neutral | kr105.31M | 25.37 | ― | ― | -5.68% | -25.31% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | kr225.79M | -5.70 | -100.09% | ― | 65.82% | 41.28% | |
41 Neutral | kr218.63M | -1.00 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr39.44M | -0.74 | 987.64% | ― | 226.89% | 57.26% | |
41 Neutral | kr26.39M | -0.15 | -57.15% | ― | ― | 16.02% |
* General Sector Average
SE:ARCOMA
Arcoma AB
7.26
-2.04
-21.94%
SE:CEVI
CellaVision AB
173.20
3.57
2.11%
SE:SCIB
SciBase Holding AB
15.90
-15.00
-48.55%
SE:QLIFE
Qlife Holding AB
1.40
-1.14
-44.90%
SE:SPEC
SpectraCure AB
0.02
-0.15
-89.16%
SE:ACARIX
Acarix AB
0.19
-0.12
-38.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.